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Airway stenting (AS) commenced in Europe circa 1987 with the first placement of a 
dedicated silicone airway stent. Subsequently, over the last three decades, AS was spread 
throughout Europe, using different insertion techniques and different types of stents.  
Objectives 
This study is an international survey conducted by the European Association of Bronchology 
and Interventional Pulmonology (EABIP) focusing on AS practice within 26 European 
countries.  
Methods 
A questionnaire was sent to all EABIP National Delegates in February 2015. National 
delegates were responsible for obtaining precise and objective data regarding the current AS 
practice in their country. The deadline for data collection was February 2016. 
Results 
France, Germany and UK are the 3 leading countries, in terms of number of centres 
performing AS. These 3 nations represent the highest ranked nations within Europe in terms 
of gross national income. Overall, pulmonologists performed AS exclusively in 5 countries 
and predominately in 12. AS is performed almost exclusively in public hospitals. AS 
performed under general anaesthesia is the rule for the majority of institutions. Local 
anaesthesia is an alternative in 9 countries. Rigid bronchoscopy techniques are predominant in 
20 countries. Amongst commercially available stents, both Dumon and Ultraflex are by far 
the most commonly deployed. Finally, 11 countries reported that AS is an economically 
viable activity while 10 claim that it is not. 
Conclusion 
This EABIP survey demonstrates that there is significant heterogeneity in AS practice within 
Europe. Therapeutic bronchoscopy training and economic issues/reimbursement for 





The main purpose of airway stenting (AS) is to restore and maintain luminal patency. Any 
endoluminal or extrinsic pathology causing more than 50% reduction in the size of the airway 
lumen can lead to debilitating symptoms such as dyspnoea. These symptoms can be 
significantly improved by the placement of an airway stent [1, 2]. Although many attempts 
were made to stent the central airway in the past [3-14], it was not until the late twentieth 
century that the commercial era of airway stenting commenced in Europe. A French doctor, 
Jean Francois Dumon was the first physician to place a dedicated and specially designed 
airway silicone stent in 1987 [15]. Subsequently, several companies developed other airway 
stents using silicone or metallic components. In the last 30 years numerous reports have been 
published describing the placement of self-expanding and balloon expandable metal stents for 
the treatment of central airway diseases [16-33].  However, despite the availability of 
additional commercial products on the market, the Dumon stent (Tracheobronxane®, 
Novatech, La Ciotat, France) remains the most commonly placed stent worldwide and the 
“gold standard” for the treatment of both benign and malignant airway stenoses over the last 
20 years. [1, 2] These stents have 2 specific designs: straight and Y-shaped (for disease 
involving the carina) [34].  Silicone stent placement requires a skill set in rigid bronchoscopy 
while metallic stents placement can be performed using flexible bronchoscopes.  
The EABIP was founded in 2002 with the objective to exchange knowledge and experience 
amongst interventional pulmonologists within Europe. This has been achieved through joint 
international multicentre research projects, establishing procedural and training standards, and 
agreeing a unified terminology to improve communication within the community of European 
Interventional Pulmonologists. A European survey was launched through the EABIP 
executive board to investigate AS practice in the 26 European countries represented by an 
EABIP national delegate. 
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Materials and Methods 
A questionnaire was developed by the EABIP board members and sent to all EABIP national 
delegates representing 26 European countries (Appendix 1). Each national delegate was 
responsible for obtaining the most precise and objective data regarding AS practice in his/her 
country.  
Statistical analysis of the data was performed using the software package IBM SPSS Statistics 
20 (Statistical Package for the Social Science). Continuous parameters are presented by means 
when normally distributed or medians and standard deviations or range. Categorical variables 
are reported as frequencies and percentages. Univariate analysis involved the use of analysis 
of variance (ANOVA) for multiple continuous variables. For the analysis of correlation 
Pearson correlation test for was used for continuous data and Spearman test for categorical 
data. Statistically significant values was considered as the level of significance of p <0.05. 
Results 
All 26 European national delegates responded to the questionnaire.  
AS (Figure 1) is performed in more than 30 centres in 3 countries (France, Germany and 
United Kingdom), between 21 to 30 centres in 2 countries (Italy and Spain), between 11 to 20 
centres in 2 countries  (Belgium and Poland), between 6 to 10 centres in 5 countries (Austria, 
Finland, Netherlands, Portugal and Switzerland), between 2 to 5 centres in 11 countries 
(Bulgaria, Denmark, Estonia, Greece, Hungary, Ireland, Norway, Romania, Slovenia, Sweden 
and Turkey) and in a single centre in 2 countries (Croatia and Serbia). In addition, since the 
close of the survey in February 2016, two more centres have started performing AS in Serbia. 
Finally one national delegate reported that AS was not performed (Macedonia). 
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With regard to the specific specialities performing AS, delegates reported that it is exclusively 
performed (Table 1) by pulmonologists in 5 countries (Croatia, Netherlands, Portugal, 
Romania, and Serbia) and predominately by pulmonologists in 12 countries (Austria, 
Belgium, Bulgaria, France, Germany, Greece, Hungary, Ireland, Norway, Sweden, 
Switzerland, and Turkey). A further 3 delegates reported that AS is mainly performed by 
thoracic surgeons (Estonia, Finland and Poland).  Finally, AS is equally performed by 
pulmonologists and thoracic surgeons in 4 countries (Italy, Slovenia, Spain and UK), and 
equally performed by thoracic surgeons and ENT surgeons in one country only (Denmark). In 
total, ENT surgeons perform AS in 14 countries (Belgium, Bulgaria, Denmark, Finland, 
France, Germany, Greece, Hungary, Italy, Norway, Poland, Sweden, Switzerland and UK). In 
addition, radiologists perform AS in 4 countries (France, Hungary, Spain and UK). 
In all countries, AS is predominately performed within the public hospital sector. In only 10 
of the 26 countries (Table 1), AS is performed in private hospitals. 
General anaesthesia is almost the exclusive mode of anaesthesia in the majority of countries; 
indeed 16 nations reported that the use of GA is exclusive. However, within the UK system 
both GA and local anaesthesia are equally utilized. Stents are placed under LA in 9 countries 
(Table 1). 
Rigid bronchoscopy is the main technique for AS in 20 countries (Table 1). Among these 20 
countries, RB is the exclusive technique in 5 countries (Croatia, Hungary, Italy, Romania and 
Slovenia) and 3 countries reported that RB and FB are equally performed (Denmark, 




Table 2 demonstrates the commercially available stents on the market in each country. 
Overall, the Dumon straight and Y –shaped stents, Polyflex, T-Tube, Ultraflex, Dynamic and 
Silmet stents are the most widely available stents.  Delegates from eight countries reported 
that there were more than 10 commercially available brands available on the market in their 
country (Austria, France, Germany, Netherlands, Spain, Sweden and Turkey). On the other 
hand, 2 countries have less than 5 commercially available stents available (Norway and 
Serbia). 
Amongst the commercially available stents (Table 2), the Dumon and the Ultraflex stents are 
by far the most commonly placed stents.  There is an almost an even split between the 
popularity of the Dumon and Ultraflex stents - The Dumon stent is ranked within the top 3 
stents in 18 countries; while this position belongs to the Ultraflex in 15 countries. After these 
two leading stents, third place is occupied by the Aerstent; which is in the top 3 rankings in 4 
countries and additionally it is the number one placed stent in an additional three countries. 
Finally five countries reported that centres also place Silmet and Microtech stents. 
In total, twelve countries report that AS is an economically viable activity while, 10 countries, 
claim that it is not financially rewarding for their health system (Table 1). 
Table 3 reports the data on global net incomes and per capita income per country. This 
demonstrates that countries with a total number of AS centers between 11 and 20 have the 
highest average global net income. Countries with 6 to 10 centers have the highest average 
per capita income. There is a statistically significant association between the number of 
centers and the average global net income of that nation (F=3,453, p=0.018). In addition, 
there is a strong statistical correlation between the number of centers per nation and it’s 
overall ranking on the global net income list (ρ=0,822, p=0,000). Finally, there was statistical 
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correlation between number of centers per nation and overall ranking on per capita income list 
(ρ=0,466, p=0,016).  
 
Discussion 
The EABIP undertook this survey to assess the current practices of airway stenting in adults 
within Europe; the birthplace of this technique.  On current geographical and political 
definitions, Europe represents a total of 51 countries; however only 26 countries have a 
national delegate represented within the EABIP.  Among these 26 countries, with a total 
population of 580 million, AS is performed in all but one country (Macedonia). 
Of the remaining 25 countries, 3 of the 4 largest nations, in terms of population, have greater 
than 30 centres practicing AS: Germany, the UK and France. It appears based on the results of 
this survey that more than 200 centres perform AS in Germany. In addition, these 3 nations 
represent the highest ranked nations within Europe in terms of gross national income (GNI).  
These results show that these countries have one AS centre for every 2.3 million population. 
Turkey, which is the third largest country in Europe, based on population (6th in terms of GNI, 
26th in terms of Per Capita Income), has only 2 to 5 centres performing AS.  However, AS is a 
relatively new procedure available in Turkey and it is possible that training is still required to 
increase the number of centres offering the technique. The Turkish national delegate stated 
that: “In Turkey, stent placement should be standardized and we will begin a certificate 
program which lasts 6 months including theoretical and practical education with the Ministry 
of Health. Interventional Pulmonology is not a subspecialty in Turkey as it is in the rest of 
Europe. However we think that education and interventions have to be strictly standardized to 
ensure a good and effective clinical approach”. 
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The next two most populated countries, Italy (4th) and Spain (5th) have between 21 to 30 
centres respectively. This represents 1 centre for every 1.8 to 2.6 million inhabitants. These 
are followed by two countries (Poland and Belgium) listed 7th and 10th respectively in terms 
of population.  These countries have between 11 and 20 centres performing AS, equating to 1 
centre for 1.23 to 2.24 million population. 
Four more countries, Austria, Finland, Portugal and Switzerland, listed 15th, 19th, 12th and 15th 
respectively in terms of population, have between 6 and 10 centres each, i.e. 1 centre for  
every 0.8 to 1.3 million population.  
Twelve countries, with close to a total population of 168 million, have between 2 to 5 centres 
performing AS. Amongst these countries there is a large heterogeneity in terms of centres per 
population; for instance, Turkey has one centre for approximately 15 million inhabitants while 
Estonia has one centre for less than 1 million people. 
Finally, two countries, Croatia and Serbia, report one centre performing AS in the country. 
This represents 1 centre per 6.25 million population. 
Therefore, in summary of the above results, this paper demonstrates that the most populated 
countries in Europe have more centres than the least populated nations. However, when the 
data is analysed per population, there is good homogeneity between all countries with roughly 
one centre for 1.3 to 2.2 millions of people, with the exception of Turkey, Croatia and Serbia. 
Even from the earliest years of Interventional Pulmonology, AS has been performed by 
different specialties: pulmonologists, ENT surgeons, thoracic surgeons and radiologists. For 
instance, JF Dumon, L Freitag and Marc Noppen are pulmonologists while William 
Montgomery was an ENT surgeon. In addition, numerous thoracic surgeons have been trained 
in this technique. In many cases this was a skill set learned by the thoracic surgeon to repair 
10 
 
post-surgical anastomotic complications but the skill was additionally used to manage central 
airway disease. Our survey has demonstrated that AS is exclusively or predominantly 
performed by pulmonologists in 17 out of the reporting 26 countries and equally performed 
by both specialty in 3 nations.  Otherwise, AS is primarily performed by thoracic surgeons in 
3 countries (Estonia, Finland, and Poland). The national delegate from Finland explained this 
finding by stating that the procedure is only economically viable if performed as a surgical 
procedure.  
Overall it is difficult to explain the variation in terms of AS operator between the European 
countries. We would suggest that each country should review their AS practices both current 
and historical as this may assist in explaining the differences in national practices. We can 
make the hypothesis that these variations are due to a number of factors that not only vary 
from country to country but also from unit to unit within a country, for example skill 
set/training of the operator, training in rigid bronchoscopy, accessibility to a dedicated unit, 
availability and ease of access to general anaesthesia, tradition, and most significantly 
reimbursement patterns in each health care structure.  However, despite these multiple factors 
it does appear that AS remains within the domain of pulmonologists in the majority of 
European countries. 
In all reporting European countries, AS is performed primarily within the public hospital 
sector.  As per our previous analysis it is unclear why this pattern exists and indeed without 
precise and exhaustive analysis of individual health services, which differ significantly from 
nation to nation within Europe, it is impossible to be certain of this result. However we have 
hypothesized that only large volume private institutions can offer the procedure at a high 
enough frequency to make it financially viable. In addition, most AS services have developed 
in institutions with onsite thoracic surgery facilities, these are often not available in medium 
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sized private hospitals. In our opinion, the presence of a thoracic surgery department is 
mandatory for a safe AS service and for interventional pulmonology will have patients who 
require stent placement after surgical interventions and in addition our surgical colleagues are 
occasionally needed to assist in the care of patients developing complications after endoscopic 
procedures.  In certain countries, current AS reimbursements are not rewarding enough for 
private structures to develop these techniques. 
In the majority of European countries, AS is performed under general anaesthesia and this 
survey has shown that the procedure is performed exclusively under GA in 16 countries. A 
further 9 countries have reported that AS can be performed under local anaesthesia. This is 
most likely explained by physician difficulty in accessing operating room facilities and 
anaesthetic cover. The lack of rigid bronchoscopy skills remains an important factor 
explaining why some centres still perform AS using flexible bronchoscopes [35]. For 
instance, in the UK, pulmonologists do not have easy access to RB as it is generally 
performed by thoracic surgeons. The recommendations of the British Thoracic Society 
guidelines [36] states that “the majority of the published case series regarding outcomes and 
complications of stent deployment are for deployment by rigid bronchoscopy only. Flexible 
bronchoscopy is an alternative to rigid bronchoscopy to deploy metallic airway stents”.  
Although NICE guidelines [37] state that all cancer centres need to provide access to airway 
stenting the subsequent British Thoracic Guidelines supported stenting under flexible 
bronchoscopy guidance. This is despite these guidelines clearly stating the significant benefits 
of rigid bronchoscopy over flexible bronchoscopy techniques. However they completed the 
guideline by stating that most clinicians did not have adequate training or a skill set in rigid 
bronchoscopy and therefore flexible procedures were acceptable. The outcome of these 
statements is that, pulmonologists in the UK continue to place metallic stents using a flexible 
bronchoscope with or without GA while surgeons are capable of placing both metallic and 
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silicone stents using rigid bronchoscopy. It is also important to recognize that rigid 
bronchoscopy is generally necessary to place stents in patients who have airway obstruction 
secondary to anything other than routine malignant tracheobronchial disease [37]. Rigid 
bronchoscopy requires either a state-of-the-art bronchoscopy suite equipped to provide 
general anaesthesia or an operating room. This scenario is rarely available to pulmonologists 
in the UK.  In addition, few operators have adequate volume to demand a dedicated session in 
the operating room. As can be expected and in particular at the early stage of service 
development, referred cases can be irregular and erratic thus leading to uncertainty in 
procedure scheduling compared to more established and higher volume surgical procedures. 
Dedicating one or two half-day lists per week for procedures allows for more consistent 
scheduling, but it does not eliminate the issue of obtaining regular operating room time [38]. 
This survey demonstrates that RB is favoured in 20 countries and equally utilized with FB in 
2 other nations. Only 2 countries favour FB. Physicians with adequate RB skills are probably 
the primary factor for deciding the type of AS procedure and stent selection.  The lack of RB 
training remains a significant factor, despite the recommendations of respiratory societies.  
The ACCP guidelines state [39] that “dedicated operators performing airway stenting should 
have extensive experience in flexible and rigid bronchoscopy and management of central 
airway lesions. To maintain competency, dedicated operators should perform at least 10 
procedures per year. In order to make the best choice for the individual patient, the dedicated 
operator should be proficient in the placement of both flexible and silicone stents. The ATS 
and ERS statement [40] wrote: “Stent insertion should be reserved for bronchoscopists who 
have had ample experience with rigid/ flexible bronchoscopy and endotracheal intubation. In 
order to maintain competence, 5–10 procedures per year should be performed”. 
The volume of procedures, in these two recommendations, is probably not enough to maintain 
competence especially if a unit is utilizing multiple stent types. Our questionnaire has shown 
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that there are 14 brands available in Europe and in addition 3 countries have locally developed 
stents available. The survey has shown that 8 countries have more than 10 types of stents 
available for use while 2 countries have less than 5 stents on the market. Surprisingly, Turkey, 
which has only 2 to 5 centers performing AS, has 13 different stent types on the market. There 
is no doubt that companies have focused on this country as an emerging market for future 
sales. 
The most widely available stents in Europe are the Dumon, Polyflex, T-tube, Ultraflex, 
Dynamic and Silmet stents. Not surprisingly, all of these stents are distributed by the two 
biggest and historically most active companies in this field: Novatech SA and Boston 
Scientific.  Of the top 3 stents, Dumon (silicone stent) is available in 18 countries, and 
Ultraflex (self-expandable nitinol stent) is available in 15 countries. These stents are clearly 
the market leaders. Other silicone stents such as the Polyflex and Noppen stents appear to 
have a limited market share while the newer brands of fully covered metallic stents such as 
Aerstent (3rd rank), Silmet (4th rank) and Microtech stents (5th rank) may need more time to 
establish themselves in this area and ultimately challenge the monopoly enjoyed by the 
Dumon and the Ultraflex stents.  
The choice of a stent, as already stated, relies not on evidence based medicine but primarily 
on the skills of the procedularist in both FB and RB, on stent availability, on overall 
commercial strategies and on other multiple subjective and expert-opinions positions.  
 
Unfortunately the growth of AS may be limited by local and national reimbursement strategy 
more than patient benefit. Overall, 12 countries stated that the procedure of AS is financially 
viable. Within these countries, financial viability relies on a combination of factors: 
commercial stent price, favourable stent and procedure reimbursement by local national 
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institutions or private insurance companies to ensure that the overall financial position for the 
institution is favourable. 
On the other hand, 10 national delegates stated that AS is not financially worthwhile in their 
jurisdiction.  For instance, in Bulgaria, the national delegate wrote that “AS is not reimbursed 
and patients have to pay for the procedure themselves (about 700 euro for a silicone stent and 
1300 euro for a metal stent). The National Health Insurance Fund pays about 450 euros for 
this interventional procedure. Therefore airway stenting is not a profit-earning activity for our 
institutions” 
The delegate from Croatia stated that “the price for stent placement is less than the cost of the 
stent itself. By including the price of dilatation and other procedures performed before stent 
placement, we can reach an amount that is greater than the price of the stent” 
In Hungary, the delegate reported that “stents are reimbursed on a case by case basis, strictly 
by the cost of the stent, without any further reimbursement. It means that it is not worth doing 
this kind of service”. In Portugal, “there is no reimbursement for stents and every time we 
place a stent the cost comes out of the hospital’s budget” 
In Romania, AS is not financially viable “because the price of the stent is very high (between 
500- 1000 Euro) comparing with the average income of people (200-300 Euro) and the price 
of the stent is not covered by health insurance. The National Health Insurance scheme does 
not pay for the interventional procedures and the reimbursement for one bronchoscopy is 
about 100 – 150 Euro, no matter how complex the procedure is (the same price for diagnostic 
and interventional procedures)”. 
The Serbian delegate stated that “our Medical Authorities do not reimburse stenting anymore 
so our procedure rate has decreased significantly”. 
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There is very little published data regarding the economic value of AS. Lund et al [37] wrote 
that, in the USA, considering the time necessary for performing advanced therapeutic 
bronchoscopy, the professional fees are not attractive. The net facility reimbursement largely 
depends on stent costs and airway stent placement is not reimbursed at competitive rates and 
may even lead to a net loss for the facility.  
 
The practice management benefits of central airway therapy are probably best obtained by a 
multidisciplinary airway team within an established cancer centre structure. It is obvious that 
airway stenting in a pulmonary practice requires expertise with other procedures and a 
substantial capital investment (e.g., for thermal ablation technology, bronchoscopes, and rigid 
bronchoscopy equipment). 
The finances of stenting and interventional bronchoscopy differ greatly between a 
multidisciplinary disease management team and a physician in private practice. Most 
reimbursement schemes will pay for a single procedure irrespective of the complexity of the 
intervention. For example, if an interventional bronchoscopy procedure requires the 
destruction of a tumour followed by a bronchoplasty with stent placement in the bronchus, the 
reimbursement is substantially lower than that obtained if each procedure was performed 
individually. 
The complexities of stenting require both rigid and flexible bronchoscopy facilities and is 
dependent on the airway disease and stent type required. Unfortunately, the skillset required, 
training, associated risks, and limited pool of technical competency in performing rigid 
bronchoscopy are not recognized.  
Improved reimbursement for bronchoscopic stent placement is required. These are high risk 
and complex procedures and are usually performed in patients with poor physiologic reserve 
and significant co-morbidities and associated poor performance status. However, current 
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reimbursement is a significant deterrent to airway stenting. Current facility reimbursement 
rules are a disincentive to developing outpatient procedures and the use of metallic stenting. 
Currently, it appears that the best business model is a hospital funded or health system-funded 
regional centre of excellence using a cost-centre approach to evaluate the real return on the 
investment. 
This survey was performed to assess the current status and practices of AS in Europe. There 
are however a number of limitations in the results.  It was not possible to collect precise data 
with respect to the indications for AS or the total number of stents placed per centre and per 
country. In some countries (UK, Poland, Denmark), the national delegate was unable to 
provide accurate data on the most popular stents placed in their region. However, the merit of 
this collaborative work is to provide a snapshot of AS practice in the 26 European members of 
the EABIP.   
It is impossible to draw accurate conclusions, guidelines or recommendations on AS practice 
given the limitations of this work and given the heterogeneity in practice and economic 
variability within countries. The EABIP has no role in the strategic planning of the health 
services of each country; however the association can support and develop AS within Europe 
by developing ongoing training programs and courses and ensuring that skills and knowledge 









Appendix 1: QUESTIONNAIRE 
- Country: 
- Population of your country? 
- Is airway stenting performed in your country?        Yes:  No: 
- If yes, and to your knowledge: 
1. How many centers in your country provide this technique? 
A : 1  
B : 2-5  
C : 6-10  
D : 11-20  
E : 21-30  
F : >30  
 
2. Who performs this technique? 
 Never Rarely Often Always 
Pulmonologists     
Thoracic 
surgeons 
    
ENT surgeons     
Radiologists     
 
3. In which institution? 
 Never Rarely Often Always 
Public 
hospital 
    
Private 
hospital 
    
 
4. Is stenting performed under local or general anesthesia? 
 Never Rarely Often Always 
Local 
anesthesia 
    
General 
anesthesia 
    
 
5. Is stenting performed using flexible or rigid bronchoscopy? 
 Never Rarely Often Always 
Flexible     






6. Commercially available stents in your country? (please tick more than one if 
appropriate)  
 Yes No 
Ultraflex stents (Boston Scientific, Natick, MA, USA)   
Aero stents (Merit Medical, South Jordan, UT, USA)   
Micro-Tech stents (Micro-Tech, Nanjing, China)   
Aerstents (Leufen, Germany)    
NiTi-stents (Taewoong Medical, Seoul, North Korea)   
Hanaro stents (M.I.Tech, Seoul, North Korea)   
Silmet stents (Novatech, La Ciotat, France)   
Dumon straight stents (Novatech, La Ciotat, France)   
Polyflex stent (Boston Scientific, Natick, MA, USA)   
Noppen stent (Reynders Medical Supply, Lennik, Belgium)   
Hood stents (Hood Laboratories, Pembroke, MA, USA)   
Dynamic Y-Stent (Boston Scientific, Natick, MA, USA)   
Dumon Y-stents (Novatech, La Ciotat, France)   
Montgomery T-Tube (Boston Medical Products, Waltham, 
MA, USA) 
  
Other (specify)   
 
7-      Among the commercially available stents in your country, which are the 3 most 
commonly placed (in decreasing order)? 
8-      Would you say that airway stent placement is economically worth in your 
country? 
a.     Yes 
b.     No 






















Table 1: Summary of national delegates answers to the questionnaire: 
GNI: global net incomes; PCI: per capita incomes; Pul: pulmonologists; TS: thoracic surgeons; ENT: ears nose and throat surgeons; Rad: 




 (millions) (rank) 
GNI  
(billion dollars) (rank) PCI (dollars) (rank) Nb centres Who Where LA/GA FB/RB 
Economically  
worth 
Austria 8 (15) 361 (12) 43901 (3) 6 to 10 Pul>TS Pub>Pri GA RB>FB No 
Belgium 11 (10) 422 (9) 40357 (6) 11 to 20 Pul>ENT Pub GA>LA RB>FB Yes 
Bulgaria 8 (15) 105 (21) 15105 (22) 2 to 5 Pul>TS=ENT Pub>Pri GA RB>FB No 
Croatia 4,5 (22) 79 (23) 17649 (21) 1 Pul Pub GA RB No 
Denmark 5 (20) 211 (17) 37942 (9) 2 to 5 TS=ENT Pub GA RB=FB Yes 
Estonia 1,31 (26) 30 (25) 23801 (17) 2 to 5 TS>Pul Pub GA>LA RB>FB Yes 
Finland 5,3 (19) 195 (19) 37105 (11) 6 to 10 TS>ENT>Pul Pub GA>LA FB>RB Yes 
France 66 (3) 2273 (3) 34305 (12) >30 Pul>TS=ENT=Rad Pub>Pri GA RB>FB Yes 
Germany 81 (1) 3227 (1) 39841 (7) >30 Pul>TS= ENT Pub GA>LA RB>FB Yes 
Greece 11 (10) 267 (15) 24788 (16) 2 to 5 Pul>TS=ENT Pub>Pri GA>LA RB>FB No 
Hungary 9,8 (13) 197 (18) 19820 (20) 2 to 5 Pul>TS=ENT=Rad Pub GA RB No 
Ireland 4,6 (23) 190 (20) 39398 (8) 2 to 5 Pul>TS Pub GA>LA RB>FB No 
Italy 61,7 (5) 1805 (4) 29264 (13) 21 to 30 Pul=TS>ENT Pub>Pri GA RB Yes 
Macedonia 2 (24) 26 (26) 10790 (25) 0 NA NA NA NA NA 
Netherlands 17 (9) 696 (8) 41256 (4) 6 to 10 Pul Pub GA RB>FB Yes 
Norway 5 (20) 282 (13) 54820 (1) 2 to 5 Pul>ENT Pub GA FB>RB No 
Poland 38,3 (7) 814 (7) 21228 (19) 11 to 20  TS>Pul=ENT Pub GA RB>FB MD 
Portugal 10,5 (12) 243 (16) 22500 (18) 6 to 10 Pul Pub>Pri GA RB>FB No 
Romania 20 (8) 281 (14) 13000 (23) 2 to 5 Pul Pub GA RB No 
Serbia 8 (15) 80 (22) 11161 (24) 1 Pul Pub GA RB+FB No 
Slovenia 2 (24) 56 (24) 28416 (15) 2 to 5 Pul=TS Pub GA RB Yes 
Spain 48 (6) 1389 (5) 29096 (14) 21 to 30 Pul=TC > Rad Pub>Pri GA RB>FB No 
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Sweden 9,5 (14) 394 (10) 40499 (5) 2 to 5 Pul>ENT Pub GA>LA RB>FB Yes 
Switzerland 8 (15) 370 (11) 45934 (2) 6 to 10 Pul>>ENT Pub>Pri GA>LA RB=FB Yes 
Turkey 75 (2) 822 (6) 10184 (26) 2 to 5 Pul>TS Pub>Pri GA RB>FB Yes 





Table 2: Commercially available as well as the 3 most placed stents per country. 
 
 
Silicone stents Hybrid stents Metallic stents 
 




Dynamic Y  Ultraflex  Aero Micro-Tech Aerstent Hanaro Silmet NiTi Others Total 












Bulgaria 1 x   2 x x x 
 
3 
     
7 




Egis (2) 8 
Denmark x   x x x x x x x x 
    
9 
Estonia 3 1   x x x x 
 
2 
    
Egis 8 







France 1 x  x x x x 3 x x x x 2 x 
 
13 
Germany 1 x x  x x x 2 
 
x x x x x 
 
13 
Greece 1 x   x x 
 





Hungary 1     x 3 x 




Ireland 2 x    x 
 
1 x 




Italy 1 x   x x x 2 




Netherlands 2 x x  x x x 3 x x 1 x x 
  
12 
Norway 3   2 x  
 
1 
       
4 







Portugal 2 x  1 x x 
 
3 




Romania 1 x   x x 
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Enbio   6 
Serbia  2   x  3 1 
       
4 
Slovenia 1 3   x x x 2 





























Turkey 1 x  x x 2 x x x 3 x x x 
 
Enbio  13 
UK x x   x x x 2 




Total 24 23 3 7 22 23 19 24 8 13 10 7 18 6 
  
 




























             N       Mean Std. Deviation Minimum Maximum Value Sig. 
   
 30+ 3 2.63 0.523 2 3   
 21 to 30 2 1.60 0.294 1 2   
 11 to 20 2 618.00 277.186 422 814   
 6 to 10 5 373.00 195.618 195 696         3.453  0.018 
 2 to 5 11 257.73 215.529 30 822   
 1 2 79.50 0.707 79 80   
 0 1 26.00 NA 26 26   
 Total 26 235.85 240.971 1 822   
 
                                               GNI rank                                PCI rank 
Number of centers     Correlation Coefficient                                             0,822                                              0,466 
                                        Significance                                                                 0,000                                              0,016 
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